Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This ...

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and ...

Investing.com -- Sandoz (SIX:SDZ) shares slid around 3% Wednesday after the Swiss drugmaker reported first-quarter 2025 sales that came in 5% below company-compiled consensus. Excluding the impact ...

It is the powerful combination of delivery and pioneering access for patients that makes us proud to be part of the Sandoz growth journey.” This guidance excludes any impacts of unforeseen events or ...

As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of "pioneering access for patients" and has benefited over 900 million patients worldwide with ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: "With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This reconfirms ...

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in biosimilar medicines and ...